Compass Pathways Plc Stock Price, News & Analysis

Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's management will deliver a presentation on August 12, 2025, at 4:00 PM ET in Boston, MA.

Investors can access the presentation through the "Events" page in the Investors section of Compass's website. The webcast recording will remain available for 30 days after the event.

Compass Pathways (NASDAQ:CMPS) reported Q2 2025 financial results and significant clinical progress. The company achieved a positive primary endpoint in its first COMP360 Phase 3 trial for Treatment-Resistant Depression (TRD), demonstrating clinically meaningful depression reduction at 6 weeks with high statistical significance. The second Phase 3 trial continues enrollment with 26-week data expected in H2 2026.

Financial highlights include a cash position of $221.9 million as of June 30, 2025, providing runway into 2027. Q2 2025 net loss was $38.4 million ($0.41 per share). The company expects FY2025 net cash used in operating activities between $120-145 million.

Research and development expenses increased to $30.3 million in Q2 2025, primarily due to advancing Phase 3 trials. The company is exploring options for potential accelerated COMP360 filing for TRD following positive trial results.

Compass Pathways (NASDAQ: CMPS), a mental health biotech company, has appointed Justin Gover to its Board of Directors. Gover brings over 25 years of biopharmaceutical leadership experience, notably as founding CEO of GW Pharmaceuticals, which he led to a $7 billion acquisition by Jazz Pharmaceuticals in 2021.

The appointment comes at a crucial time as Compass advances toward potential regulatory approval following successful Phase 3 trial results for COMP360 in treatment-resistant depression (TRD). Dr. Linda McGoldrick will retire from the Board in October 2023 after serving for over 5 years, including through the company's 2020 IPO.

Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has scheduled its second quarter 2025 financial results announcement for July 31, 2025. The company will host a conference call at 8:00 AM ET (1:00 PM UK) to discuss the financial results and provide updates on recent developments.

A live webcast will be available on the company's website and will remain archived for 30 days following the presentation.

Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the HC Wainwright @Home Series. The company's management will engage in a fireside chat with Patrick Trucchio, Managing Director Equity Research at HC Wainwright, scheduled for July 14th, 2025, at 8:00 AM ET.

Investors can access the live audio webcast through the "Events" page in the Investors section of Compass's website. The recording will remain available for 30 days after the event.

Compass Pathways (NASDAQ: CMPS) has announced positive Phase 3 trial results for COMP360, its synthetic psilocybin treatment for Treatment-Resistant Depression (TRD). The COMP005 trial, involving 258 participants across 32 US sites, achieved its primary endpoint with a statistically significant reduction in depression symptoms. A single 25mg dose of COMP360 showed a clinically meaningful difference of -3.6 points versus placebo on the MADRS scale (p<0.001). The Independent Data Safety Monitoring Board reported no unexpected safety concerns or significant differences in suicidal ideation between treatment groups. This marks a historic milestone as the first Phase 3 efficacy data for synthetic psilocybin and any classic psychedelic. A second Phase 3 trial (COMP006) continues enrollment with results expected in H2 2026.

Compass Pathways (NASDAQ: CMPS), a biotech company focused on mental health innovation, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's management will engage in a fireside chat on May 20th, 2025 at 10:30 am ET. Investors can access the live audio webcast through the "Events" page in the Investors section of Compass's website, with the replay remaining available for 30 days after the event.

Compass Pathways (NASDAQ: CMPS) reported its Q1 2025 financial results, highlighting significant progress in its psychedelic therapy development. The company reported a net loss of $17.9 million ($0.20 per share), an improvement from $35.2 million loss in Q1 2024. Key financial metrics include R&D expenses of $30.9 million, G&A expenses of $18.7 million, and a strong cash position of $260.1 million. The company's pivotal Phase 3 COMP360 psilocybin treatment program for Treatment Resistant Depression (TRD) is progressing well, with top-line 6-week data expected in late June. Recent 52-week data showed promising durability with a median time to depressive event of 92 days on a single 25mg dose. Additionally, Phase 2 results for PTSD treatment demonstrated positive safety and efficacy outcomes. The company's cash runway extends through the planned COMP006 26-week data readout in H2 2026.

Compass Pathways has partnered with HealthPort to explore delivering COMP360 synthesized psilocybin treatment in underserved communities. This strategic collaboration aims to address mental health treatment access barriers, particularly for patients with treatment-resistant depression (TRD).

HealthPort, a community health organization with 45 years of experience in Maryland's Eastern Shore, specializes in integrated care addressing social determinants of health. The partnership will:

• Research training and care reimbursement processes for COMP360
• Study implementation methods in community care settings
• Develop templates for future delivery systems

This collaboration expands Compass's network of partnerships across various healthcare settings in the United States. COMP360, their proprietary psilocybin formulation, is currently under investigation for treating difficult-to-treat mental health conditions, pending FDA approval.